New Treatments for Vascular Dementia Are Finally Arriving

More Neurology Articles

New Treatments for Vascular Dementia Are Finally Arriving

By Your Health Magazine Health Information Team

A person who once managed household bills with ease begins missing payments, struggles to follow a recipe, or seems unusually slow when making decisions. The family may assume this is ordinary aging—or that all dementia begins with memory loss. But problems with planning, attention, organization, walking, or mood can sometimes reflect damage to the brain’s blood vessels.

For years, treatment for vascular dementia focused almost entirely on preventing another stroke and helping people adapt to symptoms. That remains essential, but the field is changing. Researchers are now testing therapies aimed at small-vessel disease, blood flow, inflammation, brain recovery, and the overlap between vascular disease and Alzheimer’s disease.

Is There a New Treatment for Vascular Dementia?

The honest answer is encouraging but nuanced. There is still no medication approved by the U.S. Food and Drug Administration specifically to cure or reverse vascular dementia. However, several developments are bringing treatment closer to the underlying biology of the condition rather than addressing symptoms alone.

The most important change is a move toward personalized treatment. Vascular dementia is not one uniform disease. It may follow a major stroke, develop after multiple small strokes, or emerge gradually because of disease in the brain’s smallest blood vessels. Many people also have both vascular damage and Alzheimer-related changes. Identifying which processes are present can help clinicians choose more appropriate therapies.

Repurposed Vascular Medicines Are Showing Promise

Some of the most closely watched research involves medicines already used for other cardiovascular conditions. This can potentially shorten development time because clinicians already know a great deal about their general safety and effects elsewhere in the body.

Cilostazol, a medicine that affects platelets and blood vessels, and isosorbide mononitrate, which widens blood vessels, have been studied in people with lacunar stroke caused by cerebral small-vessel disease. A phase 2 trial produced encouraging signals involving cognition, independence, mood, quality of life, and recurrent vascular events, particularly when the medicines were evaluated together.

Larger studies are now examining whether those benefits can be confirmed. Researchers are also studying the combination specifically in people with vascular cognitive impairment. These medicines are not established treatments for vascular dementia, and they are not appropriate for everyone. Both can cause side effects or interact with other medications, so they should never be started without medical supervision.

Preventing Additional Brain Injury Remains the Foundation

A new treatment for vascular dementia does not have to be a single “dementia drug.” Because additional strokes and ongoing small-vessel damage may worsen thinking, treatment often targets the conditions harming the brain’s circulation.

• Managing high blood pressure while avoiding blood pressure that is too low
• Treating diabetes and high cholesterol
• Addressing atrial fibrillation and other heart rhythm problems
• Using antiplatelet or anticoagulant medication when medically indicated
• Stopping smoking
• Evaluating sleep apnea
• Encouraging safe physical activity and a heart-healthy eating pattern

The appropriate plan depends on whether someone has had an ischemic stroke, bleeding in the brain, atrial fibrillation, significant fall risk, or other health conditions. Preventive medications can reduce certain vascular risks, but they do not repair brain tissue that has already been damaged.

Can Alzheimer’s Medicines Help?

Clinicians sometimes prescribe donepezil, galantamine, rivastigmine, or memantine for selected people with vascular or mixed dementia. Research suggests these medications may provide small improvements in thinking for some patients, especially when Alzheimer’s disease is also present. They are not approved specifically for vascular dementia, and benefits are not guaranteed.

Newer anti-amyloid medicines are different. They target amyloid associated with early Alzheimer’s disease, not vascular damage itself. A person with confirmed Alzheimer’s pathology and vascular changes may be evaluated for one of these treatments, but careful MRI screening and ongoing monitoring are required because bleeding and swelling in the brain are meaningful risks. Someone with pure vascular dementia would not be expected to benefit from an amyloid-targeting treatment.

For a broader look at medications and research across dementia types, see this overview of current dementia treatments and emerging advances.

Rehabilitation Is Becoming Part of Active Treatment

Medication is only one part of modern care. Studies support structured physical exercise and cognitive rehabilitation as potentially helpful for mobility, daily function, and some aspects of thinking. After a stroke, rehabilitation may also help the brain develop new ways to complete tasks.

A personalized program may include:

• Physical therapy for strength, balance, walking, and fall prevention
• Occupational therapy for cooking, medication management, driving decisions, and household tasks
• Speech-language therapy for communication, attention, swallowing, or problem-solving
• Cognitive strategies such as calendars, written routines, labels, alarms, and simplified instructions
• Treatment for depression, anxiety, hearing loss, poor sleep, or pain that may worsen cognitive function

These approaches may not restore every lost ability, but they can make everyday life safer and more manageable. They can also reduce the burden on family caregivers.

Better Diagnosis May Unlock Better Treatments

Researchers increasingly use the term vascular cognitive impairment to describe a spectrum ranging from mild thinking problems to dementia. Detecting impairment before it becomes severe may provide a larger window for controlling vascular risks and supporting function.

An evaluation may involve cognitive testing, a neurological examination, medication review, laboratory tests, and brain imaging. MRI can reveal previous strokes, white-matter changes, small areas of bleeding, or other patterns that help distinguish vascular injury from Alzheimer’s disease and other conditions.

No single scan proves that vascular disease is responsible for every symptom. Clinicians must compare imaging findings with the person’s health history and pattern of decline. Comprehensive information about dementia symptoms and evaluation is also available through the MedlinePlus dementia health resource.

What Patients and Families Can Do Now

Ask whether the diagnosis is vascular dementia, Alzheimer’s disease, or mixed dementia, and whether a neurologist or stroke specialist should review the brain imaging. Bring a complete medication list to appointments, since sedating, anticholinergic, and blood-pressure-lowering medicines can sometimes contribute to confusion, dizziness, or falls.

It is also reasonable to ask about rehabilitation, caregiver education, driving safety, advance care planning, and clinical trial eligibility. Trial participation may provide access to carefully monitored research, but an experimental therapy can have unknown risks and may not offer personal benefit.

When to Seek Care

Arrange an evaluation with a primary care clinician, neurologist, geriatrician, or memory-disorders specialist when changes in planning, judgment, attention, walking, language, or memory interfere with work, finances, medications, driving, or household activities. Earlier assessment can identify treatable contributors and establish a baseline for future comparison.

Call 911 for sudden facial drooping, one-sided weakness or numbness, trouble speaking, loss of vision, severe dizziness, an abrupt balance problem, or a sudden intense headache. These may be signs of a stroke, and rapid treatment can protect both life and brain function.

A Cautious but Real Reason for Hope

The next advance in vascular dementia may not be one universal cure. It is more likely to come from combining precise diagnosis, aggressive prevention of additional vascular injury, carefully selected medications, and individualized rehabilitation. Repurposed drugs aimed at cerebral small-vessel disease are now moving through larger and more focused trials, while improved imaging is helping researchers identify the patients most likely to benefit.

That progress does not yet justify claims that vascular dementia can be reversed. It does mean that patients and families have more reason than ever to seek a thorough evaluation—and that treatment is becoming more targeted, active, and hopeful.